Chen Oleg, Michlíková Soňa, Eckhardt Lisa, Wondrak Marit, De Mendoza Adriana M, Krause Mechthild, McLeod Damian D, Kunz-Schughart Leoni A
OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany.
Department of Cell Signaling, Institute of Cell Biology, National Academy of Sciences of Ukraine, 79005 Lviv, Ukraine.
Cancers (Basel). 2021 Jun 25;13(13):3168. doi: 10.3390/cancers13133168.
Hyperthermia (HT) combined with irradiation is a well-known concept to improve the curative potential of radiotherapy. Technological progress has opened new avenues for thermoradiotherapy, even for recurrent head and neck squamous cell carcinomas (HNSCC). Preclinical evaluation of the curative radiosensitizing potential of various HT regimens remains ethically, economically, and technically challenging. One key objective of our study was to refine an advanced 3-D assay setup for HT + RT research and treatment testing. For the first time, HT-induced radiosensitization was systematically examined in two differently radioresponsive HNSCC spheroid models using the unique in vitro "curative" analytical endpoint of spheroid control probability. We further investigated the cellular stress response mechanisms underlying the HT-related radiosensitization process with the aim to unravel the impact of HT-induced proteotoxic stress on the overall radioresponse. HT disrupted the proteome's thermal stability, causing severe proteotoxic stress. It strongly enhanced radiation efficacy and affected paramount survival and stress response signaling networks. Transcriptomics, q-PCR, and western blotting data revealed that HT + RT co-treatment critically triggers the heat shock response (HSR). Pre-treatment with chemical chaperones intensified the radiosensitizing effect, thereby suppressing HT-induced Hsp27 expression. Our data suggest that HT-induced radiosensitization is adversely affected by the proteotoxic stress response. Hence, we propose the inhibition of particular heat shock proteins as a targeting strategy to improve the outcome of combinatorial HT + RT.
热疗(HT)联合放疗是提高放射治疗疗效的一个众所周知的概念。技术进步为热放疗开辟了新途径,甚至对于复发性头颈部鳞状细胞癌(HNSCC)也是如此。对各种热疗方案的放射增敏疗效进行临床前评估在伦理、经济和技术方面仍然具有挑战性。我们研究的一个关键目标是完善用于热疗+放疗研究和治疗测试的先进三维检测设置。首次使用独特的体外“治愈性”分析终点——球体控制概率,在两种对放疗反应不同的HNSCC球体模型中系统地研究了热疗诱导的放射增敏作用。我们进一步研究了热疗相关放射增敏过程背后的细胞应激反应机制,旨在揭示热疗诱导的蛋白毒性应激对整体放射反应的影响。热疗破坏了蛋白质组的热稳定性,导致严重的蛋白毒性应激。它强烈增强了放射疗效,并影响了至关重要的生存和应激反应信号网络。转录组学、定量聚合酶链反应(q-PCR)和蛋白质印迹数据表明,热疗+放疗联合治疗关键地触发了热休克反应(HSR)。用化学伴侣进行预处理增强了放射增敏效果,从而抑制了热疗诱导的热休克蛋白27(Hsp27)表达。我们的数据表明,热疗诱导的放射增敏受到蛋白毒性应激反应的不利影响。因此,我们提出抑制特定的热休克蛋白作为一种靶向策略来改善热疗+放疗联合治疗的效果。